MAS1L and hypertensive disorder: Since Ang-(1–7) possesses a short half-life in plasma, alternative Ang-(1–7) mimetics (cyclic Ang-(1–7), HPβCD-Ang-(1–7), NPA7, TXA127) and MasR agonists (AVE 0991, CGEN-856, CGEN-857) have been successfully tested in experimental models against oxidation, thrombogenesis, fibrosis, inflammation, endothelial function, and high blood pressure [71,126] (Figure 3).